AI Authoring & Study Design Vendors at DIA 2026DIA 2026 — AI 撰写与研究设计相关厂商
9 AI regulatory authoring & study design vendors confirmed presenting at DIA 2026 (Jun 14–18, Philadelphia) — compared to AuroraPrime.
9 家 AI 监管文档撰写与研究设计厂商已确认在 DIA 2026（6 月 14–18 日，费城）发表演讲，与 AuroraPrime 对比分析。
Presenting at DIA 2026
DIA 2026 出席厂商
AuroraPrime is the benchmark, not in this count
AuroraPrime 作为对标基准，不计入此数
Cover all 12 doc types
覆盖全部 12 类文档
Avg 0.9 of 12 for competitors
对手平均 0.9 / 12
Direct competitors
直接竞争
End-to-end + AI overlap
端到端 + AI 双重重叠
AI authoring sessions
AI 撰写类场次
Regulatory doc authoring & content generation
监管文档撰写与内容生成
Study-design sessions
研究设计类场次
Protocol authoring & adaptive trial design
方案撰写与自适应试验设计
Co-presentations
共同演讲
Vendor on stage with pharma / CRO / academia
厂商与 pharma / CRO / 学界同台
Trending Topics from DIA 2026 Vendor SessionsDIA 2026 厂商演讲热门主题
Keywords extracted from vendor session titles and abstracts. Chip size reflects how many sessions mention the topic.
从厂商演讲的标题与摘要中提取的关键词。芯片大小反映提及该主题的场次数量；悬停任意芯片可查看相关来源场次。
Based on 14 DIA 2026 vendor sessions · chip size = frequency · hover for context基于 DIA 2026 14 场厂商演讲 · 芯片大小 = 频次 · 悬停查看上下文
DIA 2026 presentation coverage matrixDIA 2026 演讲覆盖矩阵
Same 12 document types (Clinical / Regulatory / Safety / Communication), derived from each session's title, keywords, and abstract — what each vendor is actually talking about on the DIA stage. Compare against the product-capability matrix below to see which capabilities each vendor chose to put forward.
同样的 12 类文档（临床 / 监管 / 安全 / 沟通），但从每场 session 的标题、关键词与摘要中推导而来——反映每家厂商在 DIA 舞台上「讲了什么」。可与下方「产品能力矩阵」对比，观察哪些能力被选择性放上台前。
| Vendor · Session(s) | Clinical | Regulatory / CMC | Safety | Communication | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study Design | Protocol | ICF | CSR | M2.7/2.5 | CMC | Labeling | Non-Clin | PSN | DSUR/PBRER | LaySum | MedAffair | ||
● | ● | ● | — | ● | ● | ● | — | — | — | — | — | ||
— | — | — | — | — | — | — | — | — | — | — | — | ||
— | ● | — | ● | ● | ● | — | — | — | ◐ | — | — | ||
— | — | — | ◐ | — | — | — | — | — | — | — | — | ||
— | — | — | ● | — | ● | — | — | — | — | — | — | ||
— | — | — | — | — | ◐ | — | — | — | — | — | — | ||
— | — | — | — | — | ◐ | — | — | — | — | — | — | ||
◐ | ● | — | — | — | — | — | — | — | — | — | — | ||
● | ● | — | — | — | — | — | — | — | — | — | — | ||
● | ● | — | — | — | — | — | — | — | — | — | — | ||
— | — | — | — | — | — | — | — | — | — | — | — | ||
— | — | — | — | — | — | — | — | — | — | — | — | ||
— | — | — | — | — | — | — | — | — | — | — | — | ||
Coverage is inferred from each session's title, keywords, and abstract — it reflects what the vendor is talking about on the DIA stage, not the full capability of their commercial product (see Lifecycle coverage matrix above).覆盖范围由每场 session 的标题、关键词与摘要推断得出——反映厂商在 DIA 舞台上「讲了什么」，并不等同于其商用产品的完整能力（参见上方「生命周期覆盖矩阵」）。
DIA 2026 — Who Is Presenting at the ConferenceDIA 2026 大会演讲一览
AI-powered document authoring and study design vendors confirmed in the DIA 2026 program (Jun 14–18, Philadelphia). Session links open the official DIA 2026 agenda.
在 DIA 2026 大会（6 月 14–18 日，费城）演讲的 AI 文档生成与研究设计厂商，点击可跳转至 DIA 官方议程页面。
AI Document Generation & Regulatory AuthoringAI 文档生成与监管文件撰写
Jun 15, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 2
AI-Augmented Lifecycle — From Study Design to eCTD-Ready Submission — Featuring AI Tools Demo
This session demonstrates AI across two stages of drug development. Part 1 — AI-augmented Study Startup: from Study Design SSOT through Protocol writing to ICF, showing how AI accelerates upstream design and authoring. Part 2 — AI-orchestrated Authoring and QC across the eCTD document network: from M2.7.3 and M2.7.4 Clinical Summaries to Labeling, and from CMC Module 3 to Labeling — accelerating NDA submission. Through live demos, we show how AI discovers cross-document relationships, propagates upstream changes semantically, and delivers submission-ready coherence with a complete audit trail.
Speaker(s):演讲者：
- Sharon Chen, CEO · AlphaLife Sciences
- William Chen · AlphaLife Sciences
- Cieayrra Boozer · AlphaLife Sciences
Jun 16, 2026 · 11:45 AM – 12:15 PM · Innovation Theater 2
AI Isn't About Generating Documents, it's About Generating Data
The speakers will discuss how AI document generation is often a misunderstood problem. Sponsors focus on finding AI that can get words on a page, but they often lose sight of a broader, cross-functional, data strategy that this needs to fit within in order to achieve significant ROI. This discussion will provide a conversation around strategic adoption of AI and concrete case studies in support of that.
Speaker(s):演讲者：
- Josh Kim · Artos AI
- Sean McNiff · Vertex Pharmaceuticals, Inc.
Jun 16, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 1
Design Regulatory Grade AI — Enable Scalable, Consistent Workflows Across Document Types
Content generation is easy. Delivering outputs that are accurate, traceable, and consistent enough for regulatory submission across diverse document types is not. As teams move beyond CSR into protocol, CMC, and pharmacovigilance workflows, many AI solutions fail to adapt, creating risk around compliance, scalability, and usability. This session explores what regulatory grade AI looks like in practice. Through real workflow examples, we will show how configurable, agentic systems embed compliance and validation behind the scenes while adapting to specific business needs, enabling scalable, submission-ready outputs without compromising control.
Speaker(s):演讲者：
- Jenni Pickett, Head of Medical Writing · Yseop
- Camille Sauder · Yseop
Jun 16, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 1
The Bottleneck Has Moved — Why Successful Gen AI Implementation Isn't Just About Speed
ROI is being redefined as GenAI proliferates the regulatory writing space. While initial focus was solely on speed and accuracy, as solutions mature it's clear that time to first draft isn't the only factor that should be considered when deploying AI within your team. In this session, experts from Certara will explore how AI's rapid evolution is changing the way regulatory teams approach their workflows by pulling from real-world examples from CoAuthor implementations.
Speaker(s):演讲者：
- Nick Brown · Certara
- Christopher Kutzler · Certara
Jun 16, 2026 · 3:15 PM – 3:45 PM · Innovation Theater 1
From Point Solutions to Agentic Platform — How Life Science Companies are Rethinking AI-Driven Document Authoring and Strategy
The first wave of AI in life sciences took a document-by-document approach — one solution for the CSR, another for the IB, another for INDs and regulatory submissions. The result: fragmented tools, duplicated validation efforts, and AI that can't learn across your document ecosystem. There is a better architecture. A single AI platform that understands your internal data — clinical, CMC, safety, quality — and combines it with external regulatory intelligence to author any document type on demand. No bespoke point solutions or re-implementation for every new document class. This session draws on how top-20 pharma and medical device companies are deploying this platform approach today.
Speaker(s):演讲者：
- Surbhi Sarna, Founder & CEO · Collate
Jun 16, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 2
AI in Action — Scaling Regulatory Document Generation Across R&D
AI is no longer a future consideration — it is actively reshaping how regulatory work gets done. This session offers a practical, experience-driven perspective on how to operationalize AI for regulatory document generation. We will demonstrate how REGAIN enables flexible document creation with dynamic sectioning and customizable prompts, empowering authors while maintaining quality and consistency. Attendees will also learn key lessons from a successful collaboration — highlighting the importance of governance, cross-functional alignment, and working as one integrated team to drive adoption and deliver measurable impact across R&D.
Speaker(s):演讲者：
- Joga Gobburu, President · Vivpro Corp
- Angela Winnier · Pfizer
- Tushar Nitave · Vivpro Corp
Jun 15, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 1
The Connected Submission — How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem
Explore how AI-enabled authoring is transforming regulatory content development, delivering measurable improvements in speed, consistency, and quality across submissions. Discuss how process standardization serves as the critical enabler for automation, supporting faster, more scalable submission execution. Understand how connecting authoring, standardization, and automation enables regulatory intelligence, unlocking insights from submission content to support proactive planning and decision making.
Speaker(s):演讲者：
- Brandon Rice, Chief Executive Officer · Weave Bio
- Katie Connelly · Parexel International
Jun 16, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 2
What Survives Inspection — The Data Infrastructure That Makes AI Submission-Grade
Creating regulatory-grade submission documents using AI is more than just content generation. It requires purpose-built data infrastructure – pre-committed source bindings, replayable runs, production corrections that become training signals, and a domain-specific agent harness built for regulated workflows. Anita Modi, Co-Founder and CEO of Peer AI, walks through the architectural design that separates a writing tool from a submission platform, with case studies from real production deployments at biotech and Top 20 pharma customers. Attendees will leave with a framework for evaluating AI solutions built for sustained regulatory scrutiny.
Speaker(s):演讲者：
- Anita Modi, Co-Founder & CEO · Peer AI
AI-Powered Study Design & Clinical ProtocolAI 驱动研究设计与临床方案
Jun 15, 2026 · 10:15 AM – 10:45 AM · Innovation Theater 2
Accelerate Deep Tech Impact — Mentor Japanese MD/PhDs with Agentic AI from Startup Launch to Physician-Led Trials
Japanese MDs and PhDs possess deep tacit knowledge and clinical insights that could transform patient care, yet turning these into successful deep tech startups and physician-led clinical trials remains extremely challenging. This session introduces a powerful new approach that combines structured mentoring with Agentic AI to guide Japanese physician-scientists from idea validation and company founding through to efficient, physician-led clinical development. Participants will discover practical frameworks and real-world examples of how Agentic AI accelerates critical steps — including protocol design, regulatory navigation, and evidence generation — while experienced mentors help bridge the gap between academic excellence and market impact.
Speaker(s):演讲者：
- Shinya Yamamoto · Deep Intelligent Pharma (Singapore) Private Limited
Jun 17, 2026 · 9:15 AM – 9:45 AM · Innovation Theater 1
Digital Protocols in Action — Enabling End-to-End Automation in Clinical Development
Clinical trials still rely heavily on static Word documents to define and communicate protocol intent, creating manual handoffs, data inconsistencies, and delays across every downstream system. This session explores how digital, structured protocols serve as the foundation for end-to-end automation in clinical development, eliminating the translation layer between study design and execution. Through a live demo of the Faro platform, attendees will see how a single structured protocol definition can simultaneously drive automation across multiple workflows — from EDC build to authoring and more.
Speaker(s):演讲者：
- Vivian Dewoskin, Chief Commercial Officer · Faro Health Inc.
Jun 16, 2026 · 10:15 AM – 11:30 AM · Room 111AB
How Standardized Protocol Data Plus AI Power Patient Centric Studies
Clinical trial start-up is often delayed by manual processes, fragmented systems, and inconsistent data. This workshop will explore how biopharmaceutical companies are using AI and interoperable data standards to enable patient centric study designs.
Speaker(s):演讲者：
- William Illis · Novartis
- Vivian Dewoskin, Chief Commercial Officer · Faro Health Inc.
- Nicholas Brooke, Executive Director · The Synergist
- Sahishnu Patel · Synterex
- Prasanna Rao, Chief Products and Innovation Officer · Saama
Jun 17, 2026 · 9:15 AM – 9:45 AM · Innovation Theater 2
From Protocol to Submission — The Real-World Impact of AI in Clinical Operations
As clinical trials grow increasingly complex, relying on historical correlations and rigid fixed designs is no longer viable. This session will discuss the practical application of AI across the clinical lifecycle, from identifying predictive early-derived endpoints to dynamically optimizing site selection and patient recruitment. We will share actionable success stories demonstrating how multimodal AI platforms are currently helping biopharma and CROs navigate regulatory demands for explainability while cutting trial durations by 40%.
Speaker(s):演讲者：
- Raviv Pryluk, Co-Founder & CEO · PhaseV
Jun 15, 2026 · 10:15 AM – 10:45 AM · Innovation Theater 1
Transforming Clinical Development — Harnessing AI for Predictive Simulation and Agentic Automation
Speaker(s):演讲者：
- Raja Shankar · IQVIA
Jun 15, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 3
Accelerating Discovery — The Shift to Agentic Research Workflows with Google's Co-Scientist
In a secure Gemini Enterprise environment, Google's Co-Scientist uses multi-agent systems to accelerate breakthroughs by bridging digital data and biological insights, enabling high-velocity "Design-Test-Refine" cycles.
Speaker(s):演讲者：
- Volker Eyrich · Google
- David Henderson · Google
Source: DIA 2026 Global Annual Meeting program · diaglobal.org agenda数据来源：DIA 2026 年度大会官方议程 · diaglobal.org 议程页
Company profiles — DIA 2026 presenting vendors, product capability公司概况 — DIA 2026 参展厂商，产品能力
12 document types grouped into Clinical, Regulatory, Safety, and Communication — aligned with AlphaLife's product focus on AI-powered regulatory authoring, R&D content generation, eCTD authoring, and study design. Reflects each vendor's full commercial product (not limited to DIA presentation content); only credits AI authoring, not document management or human writing services.
12 类文档分入临床、监管、安全、沟通四组——与 AlphaLife 在 AI 监管撰写、R&D 内容生成、eCTD 撰写、研究设计上的产品聚焦一致。反映各厂商完整的商用产品能力（不限于 DIA 演讲内容）；仅记入 AI 撰写能力，不计入文档管理或人工撰写外包服务。
| Vendor | Clinical | Regulatory / CMC | Safety | Communication | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study Design | Protocol | ICF | CSR | M2.7/2.5 | CMC | Labeling | Non-Clin | PSN | DSUR/PBRER | LaySum | MedAffair | |
● | ● | ● | ● | ● | ● | ● | ● | ◐ | ◐ | ● | ◐ | |
— | — | ● | ● | ◐ | — | — | ◐ | — | — | — | — | |
— | ● | — | ● | ◐ | ◐ | ◐ | ◐ | — | — | — | — | |
— | ◐ | — | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | — | — | |
— | ◐ | — | — | — | ◐ | — | — | — | — | — | — | |
— | ● | — | ● | ◐ | ◐ | ◐ | — | — | — | — | — | |
— | ◐ | — | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | — | |
◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ | — | ◐ | |
● | ● | — | — | — | — | — | — | — | — | — | — | |
◐ | — | — | — | — | — | — | — | — | — | — | — | |
Company profiles — DIA 2026 presenting vendors公司概况 — DIA 2026 参展厂商
Company-level profiles for each confirmed DIA 2026 presenter — laid out as a comparison table for side-by-side reading. Not limited to DIA presentation content.
每家已确认参加 DIA 2026 厂商的公司层面概况，以横向对比表呈现，便于并排阅读。并非仅限于 DIA 演讲内容。
| Company公司 | Positioning定位 | Strengths优势 | Weaknesses弱点 | Customers · Recent客户 · 近况 |
|---|---|---|---|---|
Artos AI Adjacent San Francisco, CA · founded 2023 美国旧金山，CA · 成立 2023 年 Stage: 阶段：Pre-Seed Funding: 融资：$0.5M HC: 人数：5–15 (YC W24)5–15 人（YC W24） | AI platform drafting regulatory submissions (IND, PMA) in minutes by ingesting raw R&D data. AI 平台：摄入原始研发数据，分钟级生成 IND、PMA 等监管递交草稿。 |
|
| Customers: Vertex Pharmaceuticals (DIA panel reference) 客户：Vertex Pharmaceuticals（DIA 圆桌引用） Recent: DIA 2026 #522 IT (Jun 16) with Vertex — 'AI Isn't About Generating Documents, it's About Generating Data' 近期：DIA 2026 #522 IT（6/16）与 Vertex 同台——「AI 不是生成文档，而是生成数据」 |
Yseop Direct competitor Paris, France · founded ~2007 法国巴黎 · 成立 约 2007 年 Stage: 阶段：Series C+ Funding: 融资：$11M HC: 人数：90+ employees90+ 名员工 | Regulatory-Grade AI for Life Sciences — neuro-symbolic AI for medical and regulatory writing automation with deterministic auditability. 面向生命科学的「监管级 AI」——基于神经符号架构的医学与监管写作自动化，具备确定性可审计能力。 |
|
| Customers: Eli Lilly, Sanofi, Novartis, GSK 客户：Eli Lilly、Sanofi、Novartis、GSK Recent: DIA 2026 #525 IT (Jun 16) — 'Design Regulatory Grade AI'; 2025 TIME Best Inventions; 2026 BIG Innovation Award 近期：DIA 2026 #525 IT（6/16）——「Design Regulatory Grade AI」；2025 入选 TIME 最佳发明；2026 获 BIG Innovation Award |
Certara (CoAuthor) Direct competitor Princeton, NJ · founded Public (NASDAQ: CERT) 美国普林斯顿，NJ · 成立 上市公司（NASDAQ: CERT） Stage: 阶段：Public Funding: 融资：— HC: 人数：~1,000–2,000+约 1,000–2,000+ 人 | Greater Certainty in Drug Development — model-informed drug development (MIDD), biosimulation, regulatory writing (CoAuthor), and end-to-end drug-development software + services. 「让药物开发更具确定性」——模型驱动药物开发（MIDD）、生物仿真、监管写作（CoAuthor）以及端到端药物开发软件 + 服务。 |
|
| Customers: Most top-100 pharma + biotech, FDA (Pinnacle 21) 客户：大部分 top-100 药企与 biotech、FDA（Pinnacle 21） Recent: DIA 2026 #527 IT (Jun 16) — 'The Bottleneck Has Moved' (CoAuthor) 近期：DIA 2026 #527 IT（6/16）——「The Bottleneck Has Moved」（CoAuthor） |
Collate Direct competitor USA · founded Private 美国 · 成立 未披露 Stage: 阶段：Private Funding: 融资：— HC: 人数：Not disclosed未披露 | Single agentic-AI platform that authors any regulatory document on demand by combining internal clinical/CMC/safety/quality data with external regulatory intelligence. 单一 agentic-AI 平台：结合内部临床 / CMC / 安全 / 质量数据与外部监管情报，按需生成任意监管文档。 |
|
| Customers: Top-20 pharma (anonymized), Medical device companies (anonymized) 客户：Top-20 药企（匿名）、医疗器械企业（匿名） Recent: DIA 2026 #546 IT (Jun 16) — 'From Point Solutions to Agentic Platform' 近期：DIA 2026 #546 IT（6/16）——「From Point Solutions to Agentic Platform」 |
Vivpro Corporation (REGAIN) Adjacent USA · founded Private 美国 · 成立 未披露 Stage: 阶段：Private Funding: 融资：— HC: 人数：Not disclosed未披露 | REGAIN — AI-powered regulatory document automation, transforming data into submission-ready reports with dynamic sectioning and customizable prompts. REGAIN——AI 驱动的监管文档自动化，将数据转化为递交就绪报告，支持动态分节与自定义 prompt。 |
|
| Customers: Pfizer (DIA co-presenter), 60% of Top-20 pharma (claimed) 客户：Pfizer（DIA 共同演讲）、Top-20 药企的 60%（自述） Recent: DIA 2026 #524 IT (Jun 16) with Pfizer — 'AI in Action — Scaling Regulatory Document Generation Across R&D' 近期：DIA 2026 #524 IT（6/16）与 Pfizer 同台——「AI in Action：在 R&D 规模化生成监管文档」 |
Weave Bio Adjacent San Francisco, CA · founded ~2023 美国旧金山，CA · 成立 约 2023 年 Stage: 阶段：Series A Funding: 融资：$36M HC: 人数：30–60 est.约 30–60 人 | AI-native regulatory platform automating full dossier lifecycle: authoring → review → publishing → response management. AI 原生监管平台：覆盖 dossier 全生命周期——撰写 → 审阅 → 发布 → 答复管理。 |
|
| Customers: Trace Biosciences, Top 20 Pharma (anonymized), Parexel 客户：Trace Biosciences、Top 20 药企（匿名）、Parexel Recent: DIA 2026 #425 IT (Jun 15) with Parexel — 'The Connected Submission'; Oct 2025 $20M Series A 近期：DIA 2026 #425 IT（6/15）与 Parexel 同台——「The Connected Submission」；2025 年 10 月完成 $20M A 轮 |
DIP — Deep Intelligent Pharma Geographic peer Singapore · founded Private 新加坡 · 成立 未披露 Stage: 阶段：Private Funding: 融资：— HC: 人数：Not disclosed (Sequoia-backed)未披露（Sequoia 投资） | The 'AI Engine Behind China's Biotech Rise' — automating protocol design, statistical analysis, medical writing, regulatory translation, and submission management. 「驱动中国 biotech 崛起的 AI 引擎」——自动化方案设计、统计分析、医学写作、监管翻译与递交管理。 |
|
| Customers: Bayer, Merck, Roche, 1,000+ clients claimed 客户：Bayer、Merck、Roche、号称 1,000+ 客户 Recent: DIA 2026 #401.2 IT (Jun 15) — Agentic AI for Japanese MD/PhD-led trials 近期：DIA 2026 #401.2 IT（6/15）——日本 MD/PhD 主导试验的 Agentic AI |
Faro Health Upstream only San Diego, CA · founded Private 美国圣地亚哥，CA · 成立 未披露 Stage: 阶段：Private Funding: 融资：— HC: 人数：Not disclosed未披露 | The AI platform for accelerated clinical development — digital, structured protocols as the foundation for end-to-end automation from EDC build to authoring. 「加速临床开发的 AI 平台」——数字化、结构化方案作为端到端自动化的基础，覆盖 EDC 搭建到文档撰写。 |
|
| Customers: Merck (published case study), Novartis (DIA workshop co-presenter) 客户：Merck（已发表案例）、Novartis（DIA Workshop 共同演讲） Recent: DIA 2026 #601 IT (Jun 17) + Workshop #508 (Jun 16, Novartis); Jan 2026 TransCelerate award 近期：DIA 2026 #601 IT（6/17）+ Workshop #508（6/16，Novartis 同台）；2026 年 1 月获 TransCelerate 大奖 |
PhaseV Upstream only Cambridge, MA · founded Private 美国剑桥，MA · 成立 未披露 Stage: 阶段：Private Funding: 融资：— HC: 人数：Not disclosed未披露 | Causal-ML + GenAI multimodal platform for clinical-development optimization — Trial / Response / Portfolio / ClinOps Optimizers powered by 10M+ patient records. 因果 ML + GenAI 多模态平台：基于 1,000 万+ 患者层级数据，覆盖 Trial / Response / Portfolio / ClinOps Optimizer。 |
|
| Customers: Oramed, Enlivex, EMD Serono, iOMEDICO, Alimentiv, Neurosense 客户：Oramed、Enlivex、EMD Serono、iOMEDICO、Alimentiv、Neurosense Recent: DIA 2026 #602 IT (Jun 17) — 'From Protocol to Submission — The Real-World Impact of AI' 近期：DIA 2026 #602 IT（6/17）——「从方案到递交：AI 在临床运营的真实影响」 |